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Abstract
Prader–Willi syndrome (PWS) is an imprinting disorder caused by a deficiency of paternally 
expressed gene(s) in the 15q11–q13 chromosomal region. The regulation of imprinted gene 
expression in this region is coordinated by an imprinting center (PWS-IC). In individuals with 
PWS, genes responsible for PWS on the maternal chromosome are present, but repressed 
epigenetically, which provides an opportunity for the use of epigenetic therapy to restore 
expression from the maternal copies of PWS-associated genes. Through a high-content screen 
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(HCS) of >9,000 small molecules, we discovered that UNC0638 and UNC0642—two selective 
inhibitors of euchromatic histone lysine N-methyltransferase-2 (EHMT2, also known as G9a)—
activated the maternal (m) copy of candidate genes underlying PWS, including the SnoRNA 
cluster SNORD116, in cells from humans with PWS and also from a mouse model of PWS 
carrying a paternal (p) deletion from small nuclear ribonucleoprotein N (Snrpn (S)) to ubiquitin 
protein ligase E3A (Ube3a (U)) (mouse model referred to hereafter as m+/pΔS−U). Both UNC0642 
and UNC0638 caused a selective reduction of the dimethylation of histone H3 lysine 9 
(H3K9me2) at PWS-IC, without changing DNA methylation, when analyzed by bisulfite genomic 
sequencing. This indicates that histone modification is essential for the imprinting of candidate 
genes underlying PWS. UNC0642 displayed therapeutic effects in the PWS mouse model by 
improving the survival and the growth of m+/pΔS−U newborn pups. This study provides the first 
proof of principle for an epigenetics-based therapy for PWS.
PWS is clinically characterized by neonatal hypotonia and failure to thrive, childhood-onset 
obesity, intellectual disability and increased risk for psychosis in adults1. Although paternal 
deficiency of the 15q11–q13 chromosomal region is well documented as the etiology of 
PWS, the precise molecular basis underlying these clinical features remains elusive. 
Paternally expressed genes within 15q11–q13, including SNRPN, MAGEL2, NDN and 
MKRN3, and noncoding SnoRNA clusters of SNORD115 (HBII-52) and SNORD116 
(HBII-85), are controlled by a regulatory element defined as an imprinting center (PWS-
IC)2. Among these genes, the SnoRNA cluster SNORD116, located between SNRPN and 
UBE3A, plays a critical part in PWS etiology, as indicated by genomic copy-number variant 
(CNV) analyses3–6, and the specific role of MAGEL2 in PWS remains a subject of debate 
owing to conflicting findings in humans3,7–9.
SNORD116 is processed from its host transcript, a long noncoding RNA that is thought to 
initiate at the PWS-IC10. Human SNORD116 and mouse Snord116, including host 
transcripts, are highly conserved in their genomic organization and imprinted expression 
patterns10–12; yet the mechanism underlying the imprinted expressions of SNPRN and 
SNORD116 is still unclear. DNA methylation and histone modification are common 
mechanisms thought to be implicated in genomic imprinting. The differential methylation of 
CpG islands in the PWS-IC is consistent with the paternal activation of the genes, i.e., they 
are fully methylated on the maternal chromosome but unmethylated on the paternal 
chromosome13. However, histone modifications such as the acetylation of histone H3 lysine 
4 (H3K4) and the methylation of histone H3 lysine 9 (H3K9) also exhibit allele-specific 
patterns in the PWS-IC14,15. Although histone modification is expected for transcriptional 
regulation, its role in the regulation of imprinted genes is less clear and has been viewed as 
an event secondary to, or as a substitute for, DNA methylation. DNA methylation inhibitors 
can activate the expression of the maternal-originated SNRPN in vitro16, but this has not 
been reported in vivo. In addition, the inactivation of histone H3K9 methyltransferase G9a in 
mouse embryonic stem (ES) cells in vitro can induce the biallelic expression of Snprn that 
occurs with reduced DNA methylation17. Of note, DNA methylation of Snrpn is not affected 
in embryonic day 9.5 (E9.5) G9a−/− mouse embryos17,18, yet the allele-specific expression 
of Snrpn in the absence of G9a is not known in vivo. Thus, we envisioned that epigenetic 
manipulation of the PWS imprinting domain could enable the maternal chromosome to 
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express PWS-associated genes that normally show paternal-specific expression, and thus 
provide a therapeutic strategy for PWS.
RESULTS
Identification of G9a inhibitors that activate candidate PWS-associated genes by a high-
content screen
Our primary objective was to identify small molecules that are capable of activating the 
expression of SNORD116 from the maternal chromosome, and so might offer therapeutic 
benefit for PWS. However, it was not feasible to design a screening for noncoding RNA. 
SNRPN (mouse Snrpn), however, is a protein-coding gene that is expressed paternally, but 
repressed maternally, in all tissues in human and mouse19. The allele-specific expression of 
human SNRPN is regulated by the PWS-IC, which also controls the expression of host 
transcripts for SnoRNAs, including the SNORD116 cluster between SNRPN and UBE3A20. 
Thus, we decided to use the Snrpn-EGFP fusion protein (hereafter, S-EGFP) as a marker for 
a HCS campaign. We reasoned that small molecules that can activate S-EGFP might also be 
effective at activating the host transcript of Snord116. Accordingly, we established mouse 
embryonic fibroblasts (MEFs) from mice carrying S-EGFP inherited either maternally 
(mS-EGFP/p+) or paternally (m+/pS-EGFP), in which EGFP is inserted after exon 2 of the 
Snurf–Snrpn bicistronic transcript21. We confirmed that S-EGFP was expressed in 
m+/pS-EGFP and repressed in mS-EGFP/p+ MEFs (Supplementary Fig. 1a). The MEFs of 
mS-EGFP/p+ were then subjected to a HCS using a protocol that we described previously22 
(Fig. 1a). We performed the screen in quadruplicate, using 13 small-molecule libraries from 
multiple sources, including three random epigenetic-library collections (10 μM in 0.2% 
DMSO; Fig. 1b and Supplementary Table 1). We chose these libraries to ensure chemical 
diversity and pharmacological and biological activity. After employing an initial arbitrary 
cut-off of 125% (100% indicates basal fluorescence in the vehicle-treated MEFs), out of 
9,157 compounds (Fig. 1b), we identified 32 potentially active compounds from the primary 
screen (Supplementary Fig. 1b and Supplementary Table 2). Two of these compounds, 
UNC0638 and UNC0642, were validated and shown to be active in orthogonal assays of 
immunocytochemistry (Fig. 1c), concentration responses (Fig. 1d) and quantitative reverse 
transcription PCR (RT–qPCR) (Fig. 1e).
Both UN0638 and UNC0642 have been characterized as G9a- selective inhibitors that bind 
and block the catalytic domain of G9a23,24. Through an extended screening of 23 UNC0638 
and UNC0642 analogs, we subsequently identified two additional compounds: UNC617 
(Supplementary Fig. 2) and UNC618 (ref. 25) that could also activate the expression of S-
EGFP in mS-EGFP/p+ MEFs (Fig. 1c–e). UNC0638, UNC0642 and UNC617 displayed 
similar potencies in concentration-response studies (Fig. 1d; half-maximal effective 
concentration (EC50) = 1.6 μM for UNC0638, 2.7 μM for UNC0642 and 2.1 μM for 
UNC617). The estimated maximal effectiveness (Emax) was similar for these three 
compounds, whereas UNC618 was effective only at 30 μM. Next, we performed RT–qPCR 
to measure the changes in mRNA of S-EGFP. These compounds upregulated the mRNA of 
S-EGFP to an extent comparable to or greater than that induced by 10 μM of 5-aza 
deoxycytidine (5-Aza-dC), an inhibitor of DNA methyltransferases (DNMTs) (Fig. 1e). 
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Because other allele-specific histone modifications, such as acetylation, occur in the PWS-
IC16, we next examined whether the modulation of other classes of histone-modifying 
enzymes can activate S-EGFP. However, as summarized in Supplementary Table 3, we did 
not observe activation of S-EGFP in the presence of different classes of modulators. Notably, 
BIX01294 (ref. 26), the first reported G9a inhibitor, which is less potent than UNC0638 and 
UNC0642, did not have a substantial effect on the activation of S-EGFP (Supplementary 
Table 3). These data suggest that the effects of our active compounds are relatively specific 
and probably result from targeting specific histone methyltransferases.
Next, we tested whether these drugs could derepress the maternal genes in a patient-driven 
cell model of PWS: a human skin fibroblast cell line containing a typical large 5–6-Mb 
deletion of the paternal copy of the 15q11–q13 region (Fig. 2a). Because imprinting of 
SNRPN is known to be ubiquitous19, the G9a-inhibitor effect on its activation is expected to 
be representative of all tissues and cell types. Using the indicated treatment scheme (Fig. 
2b), we compared the effectiveness of four identified compounds from the HCS, including a 
control, 5-Aza-dC. All of them displayed apparent activation of SNRPN mRNA expression 
from the maternal chromosome (Fig. 2c). However, only UNC0638 and UNC0642 were 
effective for SNORD116 and the putative host transcripts for SNORD116 (116HG) and 
SNORD115 (115HG). For 116HG, multiple bands were seen in the drug-treated cells, and 
these products were further examined through subsequent Sanger sequencing. As indicated, 
some of these products were mapped to the region of 116HG (Fig. 2c), and the majority of 
the sequences were not specific or partially matched to the long-terminal-repeat sequence, a 
known sequence that requires G9a for its repression27. The UNC0638 and UNC0642 
treatments also reactivated the expression of NDN, which is 1 Mb proximal to PWS-IC. We 
were not able to determine the expressions of MAGEL2 and SNORD115, despite the 
activation of 115HG, because they are not normally expressed in skin fibroblasts28–30.
We chose UNC0638 for follow-up cell-based studies because of its high potency and 
selectivity, low toxicity and thoroughly characterized cellular activity23. UNC0638 treatment 
(1–4 μM) effectively activated SNRPN and SNORD116 transcripts, as assessed by RT–PCR 
(Fig. 2d), with minimal cytotoxicity (Supplementary Fig. 3). PWS fibroblasts treated with 4 
μM of UNC0638 expressed approximately 30% of control SNRPN protein levels (Fig. 2e 
and Supplementary Fig. 4). Taken together, these expression analyses strongly indicate that 
UNC0638 and UNC0642 are capable of activating the maternal copy of the paternally 
expressed genes from the PWS-associated region.
G9a inhibitors improved survival and growth in a mouse model of PWS
Using the m+/pΔS−U mouse model of PWS31, we next examined the effects of UNC0642 in 
vivo. Neonatal m+/pΔS−U mice display perinatal lethality and poor growth31 that resembles 
the failure-to-thrive feature of individuals with PWS during the first year of life1. We chose 
UNC0642 because it has not only high potency and selectivity for G9a in biochemical and 
cellular assays, but also excellent pharmacokinetic (PK) properties, including CNS 
penetration superior to UNC0638 (ref. 24). A single intraperitoneal (i.p.) injection dose of 5 
mg/kg of UNC0642 is sufficient to inhibit G9a activity in adult mice24. We administered the 
G9a inhibitor UNC0642 in a blinded and randomized fashion to mouse genotypes between 
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postnatal day 7 (P7) and P12, because most m+/pΔS−U pups died before weaning. For 
neonatal mice, we used a lower dosage regimen of 2.5-mg/kg i.p. injections for 5 
consecutive days (Fig. 3a). The UNC0642 treatment was well tolerated by both wild-type 
(WT) and m+/pΔS−U pups and significantly attenuated lethality in m+/pΔS−U mice as 
compared to the untreated m+/pΔS−U group (Fig. 3b). The difference in the survival rates of 
PWS pups was most notable during the first week after drug administration and diminished 
over time. Six UNC0642-treated m+/pΔS−U pups survived to >P90 (15%; n = 40), and they 
had normal physical appearance (Fig. 3c) and activity in their home cages. Body-weight 
measurements revealed that there was a significant improvement of growth between P10 and 
P19 in treated m+/pΔS-U pups (Fig. 3d). These results indicate the—albeit partial—rescue of 
lethality and growth-delay phenotypes of the PWS mouse model, and hence the potential of 
such treatment for humans.
To assess the potential toxicity associated with UNC0642 treatment, we monitored body 
weight in WT groups. Notably, loss of body weight, a sign of general health deficiency, was 
not observed in WT mice treated with UNC0642 (Fig. 3e). We also performed a general 
health and neurological screening in a blinded fashion, and it did not reveal any substantial 
abnormalities (Supplementary Table 4). In additional toxicity tests, we did not include 
vehicle-treated PWS mice because of the small sample size. Despite our breeding effort that 
produced a total number of 60 m+/pΔS−U pups, only two vehicle-treated m+/pΔS−U mice 
survived to P90. In hematological analysis, the measurements of treated m+/pΔS−U and WT 
mice were within normal ranges, as measured by liver and kidney functions as well as 
normal lipid and protein metabolism, which are indicative of normal health conditions 
(Supplementary Table 5). Histopathological analyses also did not reveal any abnormalities 
associated with UNC0642 treatment in the brain, liver, kidney, lung and heart from mice at 
P90, both in m+/pΔS−U and WT mice (Supplementary Fig. 5).
We next assessed RNA and protein expression in m+/pΔS−U mice at around P14 following 
UNC0642 treatment (Fig. 4a). The expression of Snrpn and Snord116 was readily detectable 
in the brain and liver—two organs relevant to the pathogenesis of PWS—of UNC0642 
treated m+/pΔS−U mice by RT–PCR (Fig. 4b) and quantitative reverse transcription PCR 
(RT–qPCR) (Fig. 4c), whereas vehicle-treated m+/pΔS−U mice had no detectable transcripts 
(Fig. 4b,c). We also examined whether this activation affects the maternal expression of 
Ube3a because its antisense transcript (Ube3a-ATS), which has an essential role in 
repressing the paternal copy of Ube3a in the brain, is also only paternally expressed32,33. 
Notably, the expression of Ube3a-ATS was not affected in the brain (Fig. 4c). Similarly, the 
Ube3a protein level was not changed in whole brain (Fig. 4d), or specifically, in the 
cerebellum, where the maternal-specific Ube3a transcript is predominantly expressed34 
(Supplementary Fig. 6). We also accessed the treatment effect in adulthood using the 
mS-EGFP/p+ mouse model (Fig. 4e–g). Treatment of 6-week-old mice exerted a long-lasting 
effect, as shown by the maternal expression of Snrpn–EGFP at 0 (Fig. 4f), 1, 4 and 12 weeks 
(Fig. 4g) after the final dose of UNC0642. However, it is worth noting that expression levels 
at 12 weeks were significantly lower than those at 4 weeks (P = 0.03). Therefore, these 
results demonstrate the efficacy of UNC0642 treatment in vivo for the mouse model of PWS 
and provide sufficient proof of principle to consider evaluating such a therapeutic 
intervention, targeted at the molecular etiology of PWS.
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G9a inhibitors affected H3K9 methylation but not DNA methylation in PWS domain
We next investigated the underlying mechanism for the activation of the maternal 
chromosome 15q11–q13 by UNC0638 and UNC0642. The PWS-IC is methylated on the 
maternal chromosome, but unmethylated on the paternal chromosome2. This allele-specific 
methylation is thought to implicate the imprinted regulation of candidate PWS-associated 
genes14,16. Given that G9a is also known to modulate DNA methylation via the ankyrin-
repeat domain (ANK) but not the catalytic domain of G9A35,36, we first examined the 
differential methylation to see whether the activation of the maternal genes by the G9a 
inhibitors occurs directly or through the loss of DNA modification. As expected, 5-Aza-dC 
significantly decreased DNA methylation of the PWS-IC as compared to the vehicle-treated 
group when examined by a bisulfite genomic-sequencing method (P < 0.05). By contrast, the 
UNC0638 and UNC0642 did not significantly alter DNA methylation of the PWS-IC in 
human PWS cells or in m+/pΔS−U mice, respectively, as analyzed by the bisulfite genomic-
sequencing method (Fig. 5a), which is in agreement with the previous report showing that 
UNC0638 does not alter global DNA methylation23. These data suggest that maternal 
activation is partially independent from the loss of DNA methylation, even though a dose-
dependent hypomethylation of long terminal repeats (LTRs) for individual genomic loci was 
observed in UNC0638-treated cells23.
We next examined whether these inhibitors affected the H3K9 methylation pattern. Both 
H3K9me2 (dimethylation of H3K9)15,17 and H3K9me3 (trimethylation of H3K9)37 are 
associated with the maternal chromosome in the PWS region. We verified differential 
histone modifications of the PWS-IC by a chromatin immunoprecipitation (ChIP) assay, in 
which H3K9me2 and H3ac (acetylation of H3) were enriched at the maternal or paternal 
PWS-IC, respectively (Supplementary Fig. 7). We also noted that treatment with 5-Aza-dC 
also reduced H3K9me2 in the PWS-IC of the maternal chromosome as compared to the 
vehicle-treated group (Supplementary Fig. 7). The suppression of DNA methylation thus 
seems to impair H3K9 methylation at the PWS-IC, possibly owing to the loss of interaction 
between DNMTs and G9a35,36. Using the MAGE-A2 promoter38 and a centromere sequence 
(CEN)15 as controls, UNC0638 drastically reduced the levels of H3K9me2 and H3K9me3 in 
the PWS-IC and SNORD116 regions (Fig. 5b,c). H3K9me2, but not H3K9me3, was 
enriched at the PWS-IC, and treatment with UNC0638 reduced H3K9me2 as compared to 
the untreated control cells in PWS-IC (Fig. 5b,c). The UNC0638 treatment also reduced 
H3K9me2 of other examined sites along the PWS region, including the promoter of NDN 
(Supplementary Fig. 8). At the region of the host transcript of SNORD116, both H3K9me2 
and H3K9me3 were enriched, and UNC0638 treatment reduced H3K9me2 (Fig. 5b,c) and 
H3K9me3 (Fig. 5b,d) as compared to the untreated controls.
Although G9a catalyzes primarily mono- and dimethylation reactions on H3K9 by its 
Su(var)3-9 and enhancer of zeste (SET) domain, it can contribute to the trimethylation of 
H3K9 in individual loci via an undefined biochemical mechanism39,40. This undefined 
regulation might account for the changes in H3K9me3 at the SNORD116 region. Despite the 
reduction of H3K9me2 at the MAGE-A2 promoter, we did not see the transcriptional 
activation of MAGE-A2 (Supplementary Fig. 9a). This is probably because MAGE-A2 
activation by G9a inhibitors is cell type– and treatment condition–dependent23,26. We also 
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tested the effects of the G9a inhibitor on the other imprinted loci, including maternally 
expressed CDKN1C, and paternally expressed IGF2 and PEG10. We found that the 
expression of only the paternally expressed PEG10 was modestly upregulated by the G9a 
inhibitor (Supplementary Fig. 9b). This suggests that the inhibition of G9a affects gene 
expression in a locus-selective manner, and this is consistent with the study reporting that 
only 1 of 16 imprinted loci are selectively affected in G9a−/− embryos18.
We next performed G9a chromatin immunoprecipitation (ChIP) analysis. G9a recognizes 
H3K9me2 through its ANK domains, which might amplify the spreading of H3K9me2 
(refs. 41,42). The associations of G9a with the PWS-IC and SNORD116 region were not 
significantly affected (Fig. 5e), which indicates that UNC0638 does not impair the binding 
of G9a to chromatin. Given that DNA methylation did not change in the presence of the G9a 
inhibitors, it might further suggest that the intact protein–protein interaction between ANK 
and DNMTs can still be capable of modulating DNA methylation. This idea is supported by 
previous reports showing that the ANK domain, but not the catalytic domain, of G9a is 
essential to maintaining the DNA methylation of imprinted genes35,43.
G9a-inhibitor treatment led to more open chromatin in the PWS imprinted domain
H3K9me2 facilitates heterochromatin formation to regulate transcription38,40. We thus 
investigated whether the reduction of H3K9 methylation could result in more open 
chromatin across the imprinted domain. Quantitative PCR of genomic DNA following in 
situ nuclease digestion was performed to measure chromatin accessibility (Fig. 6a), using a 
previously described protocol44. We used the following controls in this study: the 
constitutively expressed GAPDH, which was highly susceptible to nuclease digestion, and 
constitutively silent rhodopsin, which displayed minimal chromatin accessibility, regardless 
of UNC0638 treatment (Supplementary Fig. 10). As a result of the treatment with 
UNC0638, the target regions across the imprinted domains, including the SNRPN and 
SNORD116, were more open and accessible than vehicle-treated controls (Fig. 6b). The 
effect of UNC0638 and UNC0642 seemed to be bidirectional in reference to the PWS-IC in 
the PWS domain.
Taken together, these results suggest that the reduction of H3K9 methylation, but not DNA 
demethylation of PWS-IC, by the UNC0638 and UNC0642 treatment leads to more open 
chromatin, which, in turn, activates candidate PWS-associated genes from the maternal 
chromosome (Fig. 6c).
DISCUSSION
We discovered that the G9a inhibitors UNC0638 and UNC0642, identified from an unbiased 
small-molecule HCS, activate the candidate PWS-associated genes from the maternal 
chromosome both in human PWS patient-derived cells and in a mouse model of PWS. 
Treatment with UNC0642 afforded a clear therapeutic benefit for PWS-related phenotypes, 
including perinatal lethality and poor growth, which resemble the common clinical features 
of failure to thrive in individuals with PWS during the first year of life31. Further studies are 
necessary to determine whether G9a inhibitors might offer therapeutic benefit to other major 
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clinical problems of PWS, such as obesity, hyperphagia and behavioral impairment, that 
occur in childhood or later1, when appropriate animal models of PWS become available.
We also show that UNC0642 treatment does not affect the expression of Ube3a, a maternally 
expressed gene whose loss causes Angelman syndrome (AS). The activation of PWS-
associated genes on the maternal chromosome raises a concern because it may activate 
Ube3a antisense RNA (Ube3a-ATS), which normally represses paternal Ube3a 
expression32,33 but is not expressed from the maternal chromosome45. It is unclear how the 
derepression of the PWS-associated genes Snrpn and Snord116 occurs without affecting the 
expression of Ube3a-ATS. The generation and the processing of host transcripts from the 
interval between PWS-IC and Ube3a are not well understood. In contrast to the current 
notion of a long transcript IC-SNURF-SNRPN10, we speculate that the expressions of 
Snord116 host transcript and Ube3a-ATS are regulated differently. A recent study in human 
tissues from healthy individuals found potential transcription start sites (TSSs) within the 
interval between PWS-IC and UBE3A (ref. 46): one between SNORD116 and SNORD115 
clusters and another between SNORD115 and the 3′ end of UBE3A. The large host 
transcript from the PWS-IC, which overlaps with the SNRPN promoter, might stop before 
these additional TSSs, and UBE3A-ATS might be initiated from one of potential TSSs, 
probably the one close to the 3′ end of UBE3A. It seems that our G9a-inhibitor treatment 
derepresses the PWS-IC overlapping with Snrpn promoter, but not the TSS of Ube3a-ATS 
on the maternal chromosome. The continuous distribution of H3K9me2 along the PWS 
domain does not extend to the distal region47, which then makes the TSS of Ube3a-ATS not 
targetable by the G9a inhibitor. Another possibility is that the effect of the G9a inhibitor 
might become weaker at the farther end distal to the PWS-IC.
It is not well understood how the functions of histone methylation and DNA methylation are 
linked for the repression of the PWS-associated imprinting domain in vivo. A previous 
genetic study showed that the PWS-IC was demethylated in G9a-deficient embryonic stem 
(ES) cells, whereas it was not affected in G9a-deficient mouse embryos17. Unfortunately, the 
expressions of PWS-associated genes have not been examined specifically in G9a-deficient 
embryos (which died at E9.5)38, presumably owing to technical difficulties associated with 
determining their allele-specific expression in embryonic tissue. We demonstrate that the 
repressed SNRPN and SNORD116 are activated by the pharmacological inhibition of G9a, 
and that the reactivation occurred without any alteration of DNA methylation (5-
methylcytosine, 5mC) of the PWS-IC both in vitro and in vivo. It should be noted that the 
possibility of modifications other than 5mC in PWS-IC being affected by the G9a inhibitor 
cannot be ruled out because the bisulfite method used for our DNA-methylation analysis 
cannot distinguish between 5mC and 5-hydroxymethylcytosine (5hmC), or between cytocine 
(C) and 5-carboxycytosine (5CaC)48–50. Nevertheless, the finding provides novel insights 
into the regulation of imprinting, whereby H3K9 methylation has a decisive role in the 
repression of PWS-associated genes on the maternal chromosome.
We propose a chromatin-spreading model for the maternal activation of PWS-associated 
genes, in which a reduction of H3K9 methylation is sufficient for altering the chromatin 
state so that it becomes permissive to transcriptional activation. Previous genome-wide 
chromatin profiling has revealed the regions of large, organized chromatin K9 modification 
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(LOCK), including one from MKRN3 to the 3′ end of UBE3A in the PWS-associated 
imprinted domain47. We underscore in the model that reduced H3K9me2 in the PWS-IC 
initiates the spread of open chromatin along the PWS-associated imprinted region. However, 
our data do not rule out another possibility, wherein the reduced H3K9 methylation in the 
individual loci across the imprinted domain could also contribute to more open chromatin 
after G9a-inhibitor treatment.
Our findings provide a proof of principle to develop small-molecule-based epigenetic 
therapy for human PWS (Fig. 6d). From a translational perspective, the G9a inhibitor 
UNC0642 improves the life span and weight gain of m+/pΔS−U pups, produces long-lasting 
activation of PWS-associated genes, is apparently well tolerated and produces no notable 
acute toxicity, and does not interfere with the expression of the AS-associated Ube3a gene. 
For the development of new drug therapy, potential off-target effects associated with 
epigenetic drugs raise a general safety concern. The well-tolerated response to UNC0642, 
however, suggests that each case may be evaluated individually with careful consideration to 
the dose, duration, route and timing of drug delivery. The tolerability of the US Federal and 
Drug Administration–approved DNA-methylation inhibitor, observed in patients with 
myelodysplastic syndrome, is one example of the safety of an epigenetic drug51,52. It is also 
noteworthy that, in reported human cases, the disruption of multiple imprinted loci as a 
result of mutations in zinc-finger protein 57 (ZFP57), a transcriptional factor, result in only a 
relatively rare but mild condition of transient neonatal diabetes53,54, and suggests a more 
complex possibility for evaluating the broad effects of epigenetic drugs. Our study provides 
a crucial step toward the development of a specific molecular therapy for human PWS. On 
the basis of these promising results, comprehensive evaluation of the efficacy and 
tolerability of G9a inhibitors in preclinical studies is warranted to fully explore their 
therapeutic potential for treating PWS.
METHODS
Methods, including statements of data availability and any associated accession codes and 
references, are available in the online version of the paper.
ONLINE METHODS
Animals
We handled all animals for all experiments with an Institutional Animal Care and Use 
Committee (IACUC) protocol approved by Duke University. Snrpn-EGFP mice21 and the 
PWS mouse model with a paternal deletion from Snrpn to Ube3a (m+/pΔS−U)31 were 
previously described. We maintained Snrpn-EGFP mice on C57BL/6J and mice with a 
deletion from Snrpn to Ube3a (ΔS–U) on C57B6/J and 129/SvEv mixed background. We 
produced m+/pΔS−U mice and its littermates by crossing wild-type females to heterozygous 
mΔS−U/p+ male mice. Male and female mice were used in all studies.
Cell culture
To generate primary mouse embryonic fibroblasts (MEFs) carrying maternal Snrpn-EGFP 
(mS-EGFP/p+), we crossed Snrpn-EGFP/+ heterozygous females with wild-type males and 
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we isolated embryos at E12.5 to E14.5. In addition, we isolated MEFs carrying paternal 
Snrpn-EGFP (m+/pS-EGFP) from the embryos of wild-type females crossing with Snrpn-
EGFP/+ heterozygous males. We obtained human fibroblasts from patients with PWS from 
the Baylor College of Medicine cell repository and NIGMS Human Genetic Mutant Cell 
Repository. We maintained MEFs in Dulbecco’s modified Eagle’s medium (Gibco 
11995-065) supplemented with 10% FBS (Gibco 10082-147), 1% gentamicin (Gibco 
15710-064), 1% glutamine (Gibco 25030-149), 1% nonessential amino acid (Gibco 
11140-050), 0.1% β-mercaptoethanol (Gibco 21985-023), 100 units/ml penicillin and 100 
μg/ml streptomycin (Gibco 15240-062) at 37 °C and 5% CO2. We maintained human 
fibroblast cells in minimum essential medium alpha media (Gibco 12571-063) supplemented 
with 10% FBS (Gibco 10082-147), 1% L-glutamine (Gibco 25030-081), 100 units/ml 
penicillin and 100 μg/ml streptomycin (Gibco 15240-062) at 37 °C and 5% CO2.
High-content screening of small-molecule libraries
We performed high-content screening of small molecules according to the previous study22. 
Briefly, we isolated primary MEFs from E12.5–14.5 embryos of Snrpn-EGFP mice as 
described above. We maintained fibroblasts in Dulbecco’s modified Eagle’s medium 
supplemented with 10% FBS, 100 units/ml penicillin and 100 μg/ml streptomycin, at 37 °C 
and 5% CO2. 1 d before treatment with small molecules, we plated 5,000 cells per well onto 
384-well plates. On the next day, we performed screening in quadruplicate using multiple 
small-molecule libraries (Supplementary Table 1) and a compound concentration of 10 μM 
in 0.2% DMSO vehicle. 3 d after drug treatment, we imaged the immunofluorescence-
processed fibroblasts for Hoechst and AlexaFluor 488 fluorescence using a BD Pathway 855 
high-content imaging microscope. We determined antibody-enhanced S-EGPF fluorescence 
intensity in drug-treated cells individually and normalized to cells treated with vehicle 
control. We performed analysis using Cell Profiler55 with custom macro and algorithms. We 
defined potential active drugs as the increase in drug-mediated EGFP fluorescence observed 
consistently across quadruplicate wells and minimal or no cytotoxicity measured by 
Hoechst-stained nuclear structure (and the changes in total number of cells). After initial 
validation of all potential active drugs (for example, to determine whether active compounds 
show inherent fluorescence, the wild-type fibroblasts were also treated), we further validated 
only effective hit compounds in dose-response tests to determine relative efficacy (Emax) and 
potency (EC50). We analyzed the dose-response results by using Graphpad Prism (Graphpad 
Software). The calculated EC50 values (potencies) and estimated Emax (efficacy, y value top 
plateau) enabled comparative analyses of the relative potency and efficacy of the identified 
compounds.
In vitro and in vivo drug treatment
We cultured human fibroblast cells to ~80% confluence and treated them with compounds 
(UNC617, UNC0638 and UNC0642 at 4 μM; UNC618 at 8 μM; or 5-aza-dC at 10 μM final 
concentration) diluted in culture medium for 72 h. For treatment in the PWS model, we 
performed daily intraperitoneal (i.p.) injections to m+/pΔS−U litters starting at P7 and then 
for the following 5 d (UNC0642 (2.5 mg/kg), diluted in isotonic saline solution (PBS) 
containing 0.02% DMSO). We genotyped pups at the time of weaning or after their death. 
Mice of both sexes were used, and the mouse sex information is listed in Supplementary 
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Table 4. For testing chronic drug effects, we performed daily i.p. injection to 6-week-old 
mS-EGFP/p+ female mice for 7 consecutive days.
General chemistry procedure
Syntheses of UNC618, UNC0638 and UNC0642 were reported previously23–25. We 
acquired HPLC spectra for UNC617 using an Agilent 6110 Series system with UV detector 
set to 254 nm. We injected samples (5 μl) onto an Agilent Eclipse Plus 4.6 × 50 mm, 1.8 
μM, C18 column at room temperature. A linear gradient from 10% to 100% B (MeOH 
+ 0.1% acetic acid) in 5.0 min was followed by pumping 100% B for another 2 min with A 
being H2O + 0.1% acetic acid. The flow rate was 1.0 m/min. We acquired mass spectra (MS) 
data in positive-ion mode using an Agilent 6110 single-quadrupole mass spectrometer with 
an electrospray ionization (ESI) source. We acquired high-resolution mass spectra (HRMS) 
using an Aglient 6210 LCMS orthogonal-axis time-of-flight (TOF) mass spectrometer. We 
recored nuclear magnetic resonance (NMR) spectra at Varian Mercury spectrometer with 
400 MHz for proton (1H NMR) and 100 MHz for carbon (13C NMR); chemical shifts are 
reported in p.p.m. (δ). We performed preparative HPLC on Agilent Prep 1200 series with 
UV detector set to 220 nm. We injected samples onto a Phenomenex Luna 75 × 30 mm, 5 
μM, C18 column at room temperature. The flow rate was 30 ml/min. We used a linear 
gradient with 10% of MeOH (A) in 0.1% TFA in H2O (B) to 100% of MeOH (A). We used 
HPLC to establish the purity of target compounds.
Immunoblotting
We performed western blot analyses as previously described56. Briefly, we extracted total 
protein from collected tissues (liver and brain from P14–P15 mice) using modified RIPA 
buffer (1 × PBS, 1% Triton X-100, 0.1% SDS, 2 mM EDTA, and protease inhibitors). SDS–
PAGE resolved 25 μg of total proteins, and we transferred it to polyvinylidene difluoride 
(PVDF) membranes. We blocked the PVDF membranes with BLOTTO (5% skim milk and 
0.1% Tween-20 in 1× TBS buffer), and incubated with primary target antibodies, rabbit anti-
Snrpn (Protein Tech, cat. no. 11070-1-AP) at 1:400, and rabbit anti-Ube3a (Bethyl Lab, cat. 
no. A300-352A-T) at 1:1,000 working concentration in BLOTTO at 4 °C overnight. The 
next day, following incubation with horseradish peroxidase-conjugated secondary 
antibodies, we incubated the membranes with a Pierce chemiluminescent substrate and 
exposed it to X-ray film or imaged it by AI600 (GE Healthcare Life Science).
Immunocytochemistry
We performed immunofluorescence staining to detect any upregulated Snrpn-EGFP. 3 d 
after drug treatment, we fixed the cells with 4% paraformaldehyde at room temperature for 
10 min, followed by rinsing with 1× PBS. We permeabilized the cells with 0.5% Triton 
X-100 in 1× PBS at room temperature for 10 min, followed by blocking with 5% normal 
goat serum in 0.1% Triton X-100 in 1× PBS at room temperature for 30 min. We incubated 
primary rabbit anti-GFP antibody (1:1,000, Novus Biologicals cat. no. NB100-1770) at 4 °C 
overnight. The next day, we rinsed the cells with 1× PBS and incubated with goat anti-rabbit 
AlexaFluor 488 (Invitrogen cat. no. A-11008) and Hoechst at room temperature. 1 h after 
incubation, we rinsed the cells with 1× PBS and imaged for Hoechst and AlexaFluor 488 
fluorescence using a BD Pathway 855 high-content imaging microscope.
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Cell-viability assay
We analyzed cell viability measured by fluorescence using CellTox Green Cytotoxicity 
Assay (Promega, cat. no. G8741), according to the manufacturer’s instructions.
Histopathological analysis
We fixed brain, liver, lung, kidney and heart tissues from 3-month-old mice in 10% neutral 
buffered formalin (NBF: 10 ml of Formalin (37% stock), 90 ml of deionized water, 4 g/liter 
of NaH2PO4, 6.5 g/liter Na2HPO4), embedded them in paraffin, sectioned them at 5 μm, 
stained them with hematoxylin and eosin and then had a board-certified toxicological 
pathologist examine the images.
Blood chemistry and hematological analysis
We collected blood from 3-month-old mice into microcontainers or hematology assay tubes 
using jugular vein bleeding puncture. We obtained a serum metabolic panel using the Heska 
Dry Chem analyzer (Cuattro Veterinary USA). The metabolic panel contained chem and 
electrolyte, liver and kidney functions. For hematology analysis, we tested whole blood 
using Procyte (IDEXX).
Gross neurological screening
We evaluated general health using a modified version of standard test battery for behavioral 
phenotyping of mice57. Observational assessment included the evaluation of body weight, 
body core temperature, overt behavioral signs (coat appearance, body posture and secretary 
signs) and sensory functions (visual ability, audition, tactile perception and vestibular 
function). Supplementary Table 4 indicates the mouse sex and age information.
RT–PCR and RT–qPCR
For reverse-transcription PCR (RT–PCR) and quantitative real-time RT–PCR (RT–qPCR), 
first we extracted total RNA from the fibroblasts and/or collected tissues (liver and brain 
from P14–P15 mice and 7, 10 and 18-week-old m+/pS-Egfp mice) using Direct-zol RNA 
Miniprep kit (Zymo Research cat. no. R2070). We directly used 2 μg of total RNA for 
single-strand cDNA synthesis with Superscript III reverse transcriptase (Invitrogen cat. no. 
18080-093) according to the manufacturer’s protocols. The conditions for RT– PCR was 
95 °C/5 min, 35–40 cycles of 95 °C/30 s, 56–60 °C/60 s, 72 °C/60 s. We performed 
quantification of target gene expression in a LightCycler480 instrument (Roche) using 
SsoAdvanced Universal SYBR green Supermix (Biorad cat. no. 172-5271) according to the 
manufacturer’s instructions. The primers that we used in this study are listed here. SNRPN 
(forward, 5′-gctgcagcacattgactatagaat-3′; reverse, 5′-cacagtcatggataccaagttctc-3′), 
SNORD116 (forward, 5′-tggatcgatgatgagtcc-3′; reverse, 5′-tggacctcagttccgatgaga-3′), 
116HG (forward, 5′-ctggtggatcccacaggt-3′; reverse, 5′-agaagcccacgccacata-3′), 115HG 
(forward, 5′-cttcctcacaccctggtctc-3′; reverse, 5′-gacttcaagaaatgcgtgctc-3′), NDN (forward, 
5′-ggggtgggtcattatagtattcag-3′; reverse, 5′-acaaaaatccaagaaaggtagcac-3′), MAGEL2 
(forward, 5′-ctaagaagctcatcaccgaag-3′; reverse, 5′-ggcagatacgaaaccaagttg-3′), β-actin 
(forward, 5′-agagctacgagctgcctgac-3′; reverse, 5′-agcactgtgttggcgtacag-3′), mSnrpn 
(forward, 5′-ttggttctgaggagtgatttgc-3′; reverse, 5′-ccttgaattccaccaccttg-3′), mSnord116 
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(forward, 5′-ggatctatgatgattcccag-3′; reverse, 5′-ggacctcagttccgatga-3′), m116HG (forward, 
5′-ggttgcattccctttccagtatg-3′; reverse, 5′-cagcaattcccatgttccttacc-3′), mUbe3a-ATS 
(forward, 5′-acagaacaataggtcaccaggtt-3′; reverse, 5′-aagcaagactgttcacctcat-3′), GFP 
(forward, 5′-acatgaagcagcacgacttct-3′; reverse, 5′-gacgttgtggctgttgtagttgta-3′) and GAPDH 
(forward, 5′-ggcaaattcaacggcacagt-3′; reverse, 5′-gggtctcgctcctggaagat-3′).
Bisulfite genomic sequencing
We isolated genomic DNA from human PWS fibroblasts or mouse tissues at P14 or P15. We 
treated DNA (1 μg) with bisulfite using the Epi-Tect bisulfite kit (Qiagen), and we used 125 
ng of input DNA per PCR amplification. We subcloned PCR products into pGEM-T easy 
vector (Promega), and we sequenced an average of 15 clones. We analyzed DNA-sequencing 
results using BISMA web-based analysis platform (http://services.ibc.uni-stuttgart.de/
BDPC/BISMA/) with a setting for individual clones with <95% bisulfite conversion and 
<90% sequence identity to be excluded in the analysis. The primers that we used in this 
study are listed here. SNRPNbis (forward, 5′-ggtggttttttttaagagatagtttggg-3′; reverse, 5′-
catccccctaatccactaccataac-3′), Snrpnbis-outer (forward, 5′-tatgtaatatgatatagtttagaaattag-3′; 
reverse, 5′-aataaacccaaatctaaaatattttaatc-3′) and Snrpnbis-inner (forward, 5′-
aatttgtgtgatgtttgtaattatttgg-3′; reverse, 5′-ataaaatacactttcactactaaaatcc-3′).
Chromatin immunoprecipitation assay
We analyzed histone methylations on the SNRPN locus in human fibroblasts by chromatin 
immunoprecipitation assay (ChIP) using the protocol as previously reported14,15,37. We 
performed ChIP assay using the ChIP-IT Express magnetic kit (Active Motif) according to 
the manufacturer’s instructions, with modification for the fixation and reverse-cross-linking 
steps. Briefly, we prepared native chromatin without fixation and enzymatic digestions to 
average 150–500-bp-sized chromatin. We added 20 μg of chromatin to the specific 
antibodies (2 μg) or species control isotype antibodies for each immunoprecipitation 
reaction. We incubated the antibody-chromatin complexes with protein G magnetic beads 
for recovering chromatin immunoprecipitates. We purified RNase- and proteinase K–treated 
DNA using PCR purification columns (Promega). We quantified DNA recovery through 
real-time PCR performed on the LightCycler480 instrument (Roche) using SsoAdvanced 
Universal SYBR green Supermix (Biorad). We used the following antibodies: anti-rabbit 
acetylated H3 (Millipore 06-599), anti-mouse monoclonal histone H3 dimethyl K9 (Abcam 
1220) and histone H3 trimethyl K9 (Millipore, 07-442), EHMT2/G9a (Abcam ab40542). We 
performed qPCR reactions with the following cycling parameters: at 95 °C/5 min followed 
by 40 cycles of 95 °C/30 s, 60 °C/60 s. We normalized data to the total input. The primers 
that we used in this study are listed here. MAGEA2 (forward, 5′-gcctcaggatccccgtcccaat-3′; 
reverse, 5′-tggaaccggattctgcccggat-3′), CEN (forward, 5′-gtctctttcttgtttttaagctggg-3′; 
reverse, 5′-tgagctcattgagacatttgg-3′), NDN (forward, 5′-taaccctgttttccaggtatgg-3′; reverse, 
5′-aagctgctgatgagaagaaacc-3′), PWS-IC (forward, 5′-ctagaggccccctctcattgcaac-3′; reverse, 
5′-cttcgcacacatccccgcctgagc-3′), SNORD116 (forward, 5′-tcttcaaatgtgcttggatcga-3′; 
reverse, 5′-tcttcaaatgtgcttggatcga-3′), U-SNRPN (forward, 5′-caatggaccaagagcattgata-3′; 
reverse, 5′- atagggtattgaaaccccgagt-3′), SNORD116dw (forward, 5′-
tgagtcccacaaggaagttttt-3′; reverse, 5′-acattcaaagaggcaggacatt-3′), UBE3A (forward, 5′-
ttgcttcctgagcaagtcataa-3′; reverse, 5′-tccgaaagcatgacatatcaac-3′), rhodopsin (forward, 5′- 
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caagtcatgcagaagttagggg-3′; reverse, 5′-acccttataaagtgacctcccc-3′) and GAPDH (forward, 
5′-gcatcacccggaggagaaaatcgg-3′; reverse, 5′-gtcacgtgtcgcagaggagc-3′).
Chromatin accessibility assay
We performed a chromatin-accessibility assay to investigate whether G9a inhibitors change 
the open or closed state of the imprinted cluster in the PWS-IC region, according to the 
previous report44, with slight modifications. Briefly, 3 d after drug treatment in human PWS 
fibroblasts, we harvested the cells and lysed with lysis buffer (0.5% NP-40, 15 mM Tris-HCl 
(pH 7.4), 0.15 mM spermidine, 0.5 mM spermine, 15 mM NaCl, 60 mM KCl, 1 mM DTT, 
0.1mM PMSF, 0.5-M sucrose, protease and phosphatase inhibitor cocktail (Roche)). We 
collected the lysed cells by centrifugation (3,000 r.p.m./10 min/4 °C) and rinsed with 
digestive buffer (15 mM Tris-HCl (pH 7.4), 15 mM NaCl, 60 mM KCl, 4 mM MgCl2, 1 mM 
DTT, 0.1 mM PMSF, 0.35 M sucrose). After rinsing the cell pellets, we added MNase 
(NEB) to digest the open status of chromatins, followed by genomic qPCR to determine 
changes in amount of SNRPN and other imprinted genes. We defined chromatin 
accessibility using ΔCt, CtNuc(+) – CtNuc(−). The primers that we used in this study are 
described under ‘Chromatin immunoprecipitation assay.’
Statistical analysis
We used Graphpad Prism (Graphpad Software) for the statistical analyses. We used 
Student’s t test to examine the statistical significance between groups (vehicle controls 
versus drug-treated experiments). Data from multiple independent experiments were 
assumed to be of normal variance. No statistical method was used to predetermine sample 
size. Student’s t test (paired or unpaired, as appropriate) was used in Figures 1e, 2e, 3d, 
4c,d,g, 5a,c–e and 6b and Supplementary Fig. 6b, 8 and 9a,b. P < 0.05 was considered to be 
statistically significant. For the comparison of survival rates after drug treatment, we used 
the Kaplan–Meier log–rank test. For the comparison of body weight, first we used Student’s 
t test (unpaired) to examine the statistical significance between groups (vehicle controls 
versus drug-treated experiments) in Figure 3d. Then we used two-way ANOVA to test 
significance in drug treatment and genotype, including F test to determine samples with 
unequal variance. P and F values are indicated in the legend of Figure 3e. Body-weight data, 
from P7 to P10 and from P20 to P25 mice, were excluded owing to the period of drug 
administration and small samples size of PBS_PWS (n = 2), respectively. For the 
comparison of chromatin accessibility, first we used two-way ANOVA to examine the 
statistical significance in drug treatment and nuclease digestion, including an F test to 
determine samples with unequal variance. P and F values are indicated in the legend of 
Supplementary Figure 10. Then, we used Student’s t test to examine between groups 
(vehicle controls versus drug-treated experiments) in Figure 6b. ANOVA Dunnett was used 
in Supplementary Figure 3b. Data from multiple independent experiments was assumed to 
be normal variance. All data were expressed as means ± s.e.m., mean % of fluorescence 
intensity (FI) or means with max and min, as indicated. The number of mice (or cell 
cultures) in each experimental group is indicated in the figure description. Sample sizes were 
determined on the basis of review of similar experiments in in literature22,23,31,34. No data 
points were excluded, except two-way ANOVA in the comparison of body weight, as 
described above.
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Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Identification of small molecules that activate the expression of Snrpn from the maternal 
chromosome. (a) Screening strategy using a cell-based model. (b) Summary of all 9,157 
compounds (pie chart, left) and data plot including constitutively active paternal S-EGFP as 
a positive control (dot plot, right). We highlighted two active compounds (data are mean % 
of fluorescence intensity (FI) ± s.e.m.; red dotted line indicates a cutoff of 1.25). (c) 
Representative images (n = 4 cultures for each drug tested) of maternal Snrpn-EGFP MEFs 
at the presence of the compounds and their chemical structures. Scale bars, 100 μm. (d) 
Concentration-response curves of UNC0638 (red), UNC0642 (blue) or UNC617 (orange) in 
maternal S-EGFP MEFs (n = 4 cultures per each point of dose; data are means ± s.e.m. of 
three independent experiments). (e) Validation of Snrpn-EGFP mRNA expressions in G9a 
inhibitor- or 5-Aza-dC-treated MEFs using RT–qPCR (Livak methods, normalization to β-
actin, Student’s t test; **P < 0.01; n = 4 cultures per group, data are means ± s.e.m. of three 
independent experiments).
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Figure 2. 
UNC0638 activates the expression of candidate PWS-associated genes in fibroblasts derived 
from individuals with PWS. (a) Schematic of genomic organization of PWS-associated 
imprinted domain at the human chromosome 15q11–q13 (IC, imprinting center). (b) 
Schematic of in vitro treatment used in c–e. (c) Representative RT–PCR analysis (n > 10 
independent experiments for SNRPN and SNORD116 and n = 3 independent experiments 
for the other genes and transcripts from 15q11–q13) in human PWS fibroblasts treated with 
UNC0638, UNC0642, UNC617, UNC618 or 5-Aza-dC (ctrl, control; 116HG, host transcript 
for SNORD116; 115HG, host transcript of SNORD115; RTase: +/−, with or without reverse 
transcriptase; M, 1kb DNA ladder). (d) Representative RT–PCR (n > 10 for SNRPN and 
SNORD116) (top) and concentration-response curves (bottom; n = 3 cultures per each point 
of dose; data are means ± s.e.m. of two independent experiments) of SNRPN and 
SNORD116 in UNC0638-treated human fibroblasts. UNC0638 activated the expression of 
SNRPN and SNORD116 in PWS fibroblasts (PWS cell line derived from an individual with 
PWS carrying a 6-Mb paternal deletion of chromosome 15q11–q13; ctrl, from an individual 
without PWS; M, 1-kb DNA ladder). (e) Cropped representative western blot (n = 3 cultures 
per group of two independent experiments) (top; the original blot is shown in Supplementary 
Fig. 4) and quantification of the SNRPN protein (bottom) in human PWS fibroblasts with or 
without UNC0638 (0638) treatment. Student’s t-test; ***P < 0.0001; data are means ± s.e.m.
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Figure 3. 
UNC0642 improves survival and growth in a mouse model with a paternal deletion from 
Snrpn to Ube3a (m+/pΔS−U). (a) Schematic of in vivo treatment of m+/pΔS−U mice in b–e. 
(b) Improved survival of UNC0642-treated m+/pΔS−U pups (Kaplan–Meier log–rank test, P 
= 0.001; χ2 = 15.0039; df = 1; data are percentage of survival). (c) The normal appearance 
of UNC0642-treated m+/pΔS−U and PBS-treated wild-type (WT) mice at P90. (d) Changes 
in weight gain in m+/pΔS−U mice with or without the treatment of UNC0642. Box-and-
whisker plots correspond to body weight of PBS-treated m+/pΔS−U (open blue, n = 25 mice 
at P7 and n = 2 mice at P25); UNC0642-treated m+/pΔS−U (blue, n = 27 mice at P7 and n = 6 
mice at P25) (Student’s t test; *P < 0.05; between two groups of PWS_UNC0642 and 
PWS_PBS from P10 to P19). (e) Changes in weight gain in WT mice with or without the 
treatment of UNC0642 (open black line, n = 22 mice at P7 and n = 22 mice at P25); treated 
WT (black, n = 14 mice at P7 and n = 14 mice at P25). Two-way ANOVA; treatment; P < 
0.0001; F = 863.3, genotype; P < 0.0001; F = 14.86, interaction; P < 0.0001; F = 2.86 from 
P10 to P19; data are means with max and min.
Kim et al. Page 20
Nat Med. Author manuscript; available in PMC 2017 September 07.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 4. 
UNC0642 activates candidate PWS-associated genes in mouse models with a paternal 
deletion from Snrpn to Ube3a (m+/pΔS−U). (a) Schematic of in vivo treatment of m+/pΔS−U 
mice for b, c, and d. (b) Representative RT–PCR analysis of Snrpn and Snord116 in the 
brain and the liver in a mouse model of PWS treated with UNC0642. UNC0642 activated 
the expression of Snrpn and Snord116 (RT: +/−, with or without reverse transcriptase; three 
independent experiments). (c) Representative RT–qPCR analysis (n = 4 mice per group from 
six independent experiments for Snrpn and Snord116 and three independent experiments for 
116HG and Ube3a-ATS) of the brain and the liver in mouse models of PWS treated with 
UNC0642. UNC0642 activated Snrpn, and Snord116, but not Ube3a-ATS (Student’s t test; 
*P < 0.05; n = 4 per group, data are mean ± s.e.m.). (d) Cropped representative western blot 
analysis (n = 3 mice per group with two independent experiments) (top; the original blot is 
shown in Supplementary Fig. 6a) and quantification (bottom; expression levels were 
normalized to β-actin). The level of SNPRN but not UBE3A protein was significantly 
increased after treatment (Student’s t test; *P < 0.05; n = 3 per group, data are means ± 
s.e.m. two independent experiments). (e) Schematic of treatment in 6-week-old mice for 
examining long-term activation of maternal genes in f and g. (f) Representative RT–PCR 
analysis (n = 3 mice per group, with three independent experiments) of S-EGFP in the brains 
of mice carrying imprinted S-EGFP. UNC0642 derepressed S-EGFP after 1 week of 
treatment (RT: +/−, with or without reverse transcriptase; three independent experiments). 
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(g) Representative RT–qPCR analysis (n = 3–5 mice per group, with two independent 
experiments) of S-EGFP in the brains of mice carrying imprinted S-EGFP. Student’s t test; 
*P < 0.05; **P < 0.01; data are means ± s.e.m.
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Figure 5. 
The activation of candidate PWS-associated genes by UNC0638 and UNC0642 is associated 
with demethylation of H3K9. (a) Comparison of the DNA methylation in PWS-IC between 
vehicle- and UNC0642- or UNC0638- treated in liver of m+/pΔs−u mice and in a human 
PWS fibroblast cell lines. Left, black square indicates methylated, and gray square 
unmethylated, CpG sites. Right, the average methylation measured by the number of 
methylated CG sites divided by the total number of CG sites analyzed (Student’s t test; *P < 
0.05; n = 7–16 clones per group; data are means ± s.e.m. of three independent experiments). 
(b–d) Changes in repressive histone marks associated with the activation of the maternal 
SNRPN and SNORD116 in PWS fibroblasts. (b) Genomic DNA PCR following chromatin 
immunoprecipitation of H3K9me2 or H3K9me3 in PWS fibroblasts. The recovery of DNA 
indicates its binding with the histone modification in the absence (open arrowheads) or 
presence (arrows) of UNC0638 as both MAGE-A2 (MAGE) and centromere (CEN) serve as 
control (Inp, input; Ig, IgG isotype control; K9me2, histone H3 lysine 9 dimethylation; 
K9me3, histone H3 lysine 9 trimethylation; B, bound fraction; UB, unbound fraction). (c,d) 
ChIP–qPCR quantification of H3K9me2 (c) and H3K9me3 (d). Data showed the enrichment 
over IgG and the fold change of H3K9me2 and H3K9me3 in UNC0638-treated cells. (c; 
K9me2/log2FC: Student’s t test; **P < 0.01; n = 3 cultures per group, data are means ± 
s.e.m. of three independent experiments. d; K9me3/log2FC: Student’s t test; **P < 0.01; n = 
3 cultures per group, data are means ± s.e.m. of three independent experiments). (e) Stable 
G9a binding in ChIP. G9a binding was not changed in the PWS fibroblasts treated with 
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UNC0638 (Student’s t test); n = 3 cultures per group, data are means ± s.e.m. of two 
independent experiments).
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Figure 6. 
Activation of candidate PWS-associated genes by UNC0638 and UNC0642 is associated 
with enhanced chromatin accessibility. (a) Experimental scheme for assessing chromatin 
accessibility. (b) Increased chromatin accessibility in the PWS imprinted domain by 
UNC0638. GAPDH (active) and rhodopsin (silent) genes serve as controls for chromatin 
that is highly susceptible versus resistant to nuclease digestion (data set of nuclease 
sensitivity shown in Supplementary Fig. 10). The chromatin at the genomic loci of PWS-IC, 
SNORD116 and NDN, but not UBE3A, was more accessible after UNC0638 treatment. 
(GAP, GAPDH; Nuc, Nuclease; Chr, chromatin. Student’s t test; **P < 0.01; n = 3 cultures 
per group, data are means ± s.e.m. of two independent experiments). (c) A schematic 
chromatin-spreading model for maternal activation of the candidate PWS-associated genes 
in response to G9a inhibitor. Top, on the paternal chromosome, a widely open chromatin 
structure allows for gene transcription (for example, NDN, SNRPN and SNORD116). 
Bottom left, on the maternal chromosome, G9a-mediated methylation of H3K9 can 
propagate in a bidirectional manner along the PWS-associated genes. A compact, closed 
chromatin structure suppresses gene transcription of paternally expressed genes. Bottom 
right, UNC0642 or UNC0638 induces the opening of chromatin structure through the 
reduction of H3K9 methylation, which derepresses the expression of PWS-associated genes. 
(d) A proof of principle of epigenetic therapy for PWS via the G9a inhibitor. UNC0638 and 
UNC0642 (blue dots) directly reduce H3K9 methylation (red stars), but do not change 
methylated PWS-IC (black hexagon). The reduction of H3K9 methylation would be 
sufficient to activate PWS-associated genes, and thereby offer therapeutic benefits.
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